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Abstract
Background: Bluetongue (BT) is a vector-borne disease of ruminants caused by bluetongue virus that is transmitted by
biting midges (Culicoides spp.). In 2006, the introduction of BTV serotype 8 (BTV-8) caused a severe epidemic in Western and
Central Europe. The principal effective veterinary measure in response to BT was believed to be vaccination accompanied by
other measures such as movement restrictions and surveillance. As the number of vaccine doses available at the start of the
vaccination campaign was rather uncertain, the Dutch Ministry of Agriculture, Nature and Food Quality and the Dutch
agricultural industry wanted to evaluate several different vaccination strategies. This study aimed to rank eight vaccination
strategies based on their efficiency (i.e. net costs in relation to prevented losses or benefits) for controlling the bluetongue
virus serotype 8 epidemic in 2008.
Methodology/Principal Findings: An economic model was developed that included the Dutch professional cattle, sheep
and goat sectors together with the hobby farms. Strategies were evaluated based on the least cost - highest benefit frontier,
the benefit-cost ratio and the total net returns. Strategy F, where all adult sheep at professional farms in the Netherlands
would be vaccinated was very efficient at lowest costs, whereas strategy D, where additional to all adult sheep at
professional farms also all adult cattle in the four Northern provinces would be vaccinated, was also very efficient but at a
little higher costs. Strategy C, where all adult sheep and cattle at professional farms in the whole of the Netherlands would
be vaccinated was also efficient but again at higher costs.
Conclusions/Significance: This study demonstrates that a financial analysis differentiates between vaccination strategies
and indicates important decision rules based on efficiency.
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Introduction
Bluetongue (BT) is a non-contagious, vector-borne disease of
ruminants and camelids caused by bluetongue virus (BTV) that is
transmitted by biting midges (Culicoides spp.) [1]. Animals, in
particular sheep, can develop severe clinical symptoms as a result
of the infection. Due to the economic damage historically
associated with Bluetongue, it was listed as a notifiable disease
by the World Organization for Animal Health (OIE) in the 1960’s.
As a consequence, the OIE standards require that all international
movements of animals of susceptible species and their potential
infectious products from infected countries and zones are
forbidden unless they are demonstrated to be non-infected after
a specified period of protection from vector attacks in an insect-
proof environment [2].
In 2006, the introduction of BTV serotype 8 (BTV-8) caused a
severe epidemic in Western and Central Europe [3]. Although a
comprehensive set of control measures (including obligatory
indoor housing, treatments with insecticides, trade restrictions like
restrictions on animal movements and extra testing and controls
on export animals) was put in place at the national and the
European Union (EU) level in 2006, the infection reappeared after
a mild winter and spring in 2007. The epidemic developed quickly
over a large part of Western and Central Europe, affecting
approximately 40,000 locations with ruminants [4].
Vaccination has been demonstrated to be an effective tool to
control the spread of BT [5]. The European Commissioner for
Health, Markos Kyprianou, stated at the EU Conference on
‘‘Vaccination Strategy against Bluetongue (16 January 2008)’’ that
the principal, and possibly the only, effective veterinary measure in
response to BT is vaccination accompanied by ancillary measures
such as movement restrictions and surveillance. The scale of the
epidemic in 2007 was so large that an emergency vaccination
campaign was started in May and June of 2008 in several EU
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Germany and Luxembourg a mandatory vaccination campaign
was initiated, in others like Britain and the Netherlands a
voluntary campaign was promoted [9]. The emergency vaccina-
tion campaign against BTV-8 in 2008 was financially supported by
the EU, as laid down by Decision 2008/655/EC [10].
As the number of vaccine doses available at the start of the
vaccination campaign was rather uncertain, the Dutch Ministry of
Agriculture, Nature and Food Quality and the Dutch agricultural
industry wanted to evaluate several different vaccination strategies.
This evaluation should focus on the costs and benefits for the year
of vaccination It should include all financial costs and benefits of a
wider farm perspective, including the affected farm sector (cattle,
sheep and goats), the affected related industry and the control
authorities, which are either paid by the government, animal
health authorities or the farmers and firms. Therefore, the
objective of this study was to rank different possible vaccination
strategies based on the efficiency (i.e. net costs in relation to
prevented losses or benefits) for controlling the BTV-8 epidemic in
the period July 2008 to July 2009 to support animal health
authority in their decision making.
Materials and Methods
For the financial analysis the following steps were followed.
First, the different vaccination strategies were defined. Second, the
financial impact of a BTV-8 epidemic in 2008 (i.e. from July 2008
to July 2009) was quantified under the condition that no
vaccination strategy would be applied. Third, the reduction in
financial impact of the BTV-8 epidemic in 2008 due to the
application of a vaccination strategy was quantified. Fourth, the
costs of the defined vaccination strategies were calculated. Fifth,
the different vaccination strategies were ranked based on economic
criteria. And sixth, a sensitivity analysis was performed.
Vaccination strategies evaluated
Eight vaccination strategies were determined by veterinary
epidemiologists who were closely involved with the Dutch BTV-8
epidemic. They advised the Dutch government during the
epidemic based on their knowledge which was obtained from
on-going epidemiological research during that period and from
international literature and discussion groups. During a discussion
meeting the epidemiologists decided on the strategies evaluated.
These strategies were considered in the decision making process
and were based on the uncertain knowledge on the number of
vaccine doses available in June 2008. This uncertainty forced the
decision makers to think about vaccinating sub groups, e.g.
differentiate in age and/or regions (e.g. the Northern part of the
Netherlands was most susceptible at the end of 2007 and should be
prioritized for vaccination [11]) and/or farm type (professional
and/or hobby farms). The eight defined vaccination strategies are:
A, Vaccination of all sheep, cattle and goats of the Netherlands; B,
vaccination of all adult sheep, cattle and goats of the Netherlands;
C, vaccination of all adult sheep and cattle at professional farms in
the Netherlands; D, vaccination of all adult sheep at professional
farms of the Netherlands and all adult cattle in the four Northern
provinces (Groningen, Friesland, Drenthe and North Holland); E,
vaccination of all adult cattle at professional farms in the
Netherlands; F, vaccination of all adult sheep at professional
farms in the Netherlands; G, vaccination of all adult cattle at
professional farms in the four Northern provinces; H, vaccination
of 80% of the adult sheep and cattle in the Netherlands.
Strategies A and B were based on unlimited availability of
vaccine doses. Strategy C was based on the availability of three
million doses. Strategies D and E were based on availability of two
million doses and strategy F and G on availability of one million
doses. Strategy H differs from the others. In this scenario a
voluntary vaccination program is assumed with the expectation
that 80% of the sheep and cattle owners would decide to
vaccinate. All other programs were assumed to be obligatory with
the expectation that 100% of the animals owners who should
vaccinate, would vaccinate.
Estimation of the benefits of the vaccination strategies
The economic benefit of vaccination against BTV-8 is defined
as the reduction of potential damage or financial impact due to
vaccination caused by a BTV-8 epidemic in the cattle, sheep and
goat sectors from July 2008 to July 2009. The reduction in losses
due to vaccination can be calculated based on the estimated
damage in a situation where no vaccination strategy would be
applied, which is indicated with scenario ‘BT2008-NV’. All
vaccination scenarios and the BT2008-NV scenario take account
of the same specific starting situation, which is the number of non-
infected farms the winter of 2007/2008 in the Northern, Middle,
and Southern part of the Netherlands. At this time the virus has
already infected 94% of all cattle holdings, 70% of all sheep
holdings and 47% of all goat holdings [11]. In the BT2008-NV
scenario it is assumed that all non-infected farms (i.e. not infected
during the epidemics of 2006 and 2007) would be infected in 2008
if no vaccination strategy would be applied, i.e. a worst case
scenario. For the farms that were infected before, we assumed that
a new infection in 2008 will have negligible effect based on the
observation that farms infected in 2006 had negligible health
problems due to BTV-8 during the epidemic of 2007.
The financial impact of the BT2008-NV epidemic is calculated
using the economic model as described in Velthuis et al. [11]. The
deterministic model includes all costs and benefits of affected farms
(cattle, sheep and goats), affected related industries (like dairy
companies, slaughterhouses or export related firms) and the
control authorities. As at the time of this study no losses or benefits
due to the BTV-8 epidemic were identified for dairy companies
and slaughterhouses, they were not in the model and will not be
presented in the results of this study.
The model calculates the net costs or financial impact of Dutch
BTV-8 epidemics by integrating demographic, epidemiologic and
economic data.In addition,it is compatible with the Dutchlivestock
production systems for cattle, sheep and goats, including the hobby
holdings. Three different regions were distinguished in the model,
namely North, Central and South. as numbers of farms and farm
sizes varied among the regions as well as the observed BT morbidity
and mortality rates. The northern region includes the provinces of
Friesland, Groningen, Drenthe and North Holland, the central
region comprises the provinces of Gelderland, Overijssel, Flevoland
and Utrecht, and the southern region of the provinces of North
Brabant, South Holland, Zeeland and Limburg.
The net costs of a BTV-8 epidemic (L) include the impact of BT
on production (Pi,j) for farm type i and animal type j, treatment of
diseased animals (Ti,j), diagnostic costs (Di), and costs of control
measures adopted during the course of the epidemic, including
price changes for animals and animal products due to transport
restrictions (Mi,j):
L~
X
i
X
j Pi,jzTi,jzDizMi,j ð1Þ
Details of the calculations are given in Velthuis et al. [11], whereas
in the following paragraphs only the main assumptions and
changes are described.
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included mortality, early culling, reduced milk production, weight
loss, no gestations, postponed gestations, abortions, less fertile
sheep rams, lower birth weights, and stillbirths.
The treatment cost (Ti,j) included costs of the veterinary
medicines and application materials. Costs for the veterinarian
were not included in the treatment costs but in the costs for
diagnosis. This is because most sick animals are treated during the
(first) visit where BTV-8 is diagnosed. Furthermore, it is assumed
that subsequent treatments were applied by farmers where it is
assumed that there are no opportunity costs for this labour. To
relieve the suffering and to prevent secondary infections as a result
of reduced immunity, part of the BTV-8 diseased animals were
treated with pain killers, antibiotics or corticosteroids. If a dairy
cow was treated with antibiotics the calculations also included
additional losses due to the fact that milk cannot be delivered for
some period.
Diagnostic costs (Di) included the costs of veterinary labour
(state and/or private veterinarian), sampling materials and test
costs (including the submission costs to the lab). The official BTV-
8 diagnosis for 2008 was based exclusively on clinical inspections
by private veterinarians, like it was defined from October 2007.
However, a number of samples was still submitted to the lab and
were therefore included in the calculations.
The control measures for livestock farms in various control
zones around infected farms that were applied in 2007 were
assumed to be applied in 2008 too. These measures include
treatment of animals, stables and vehicles for animal transport
with insecticides, extra testing and control of animals for export,
and restrictions on animal movements. The losses due to
restrictions on animal movement were considered to be equivalent
to the price changes of animals and animal products because they
affect either the supply or demand in a region which consequently
leads to price changes. An autoregressive integrated moving
average model was used to test if changes in the National average
monthly prices are related to the estimated number of farms in
restriction zones. For this, monthly data of the years 2004, 2005
and 2006 were used to correct for normal seasonal influences.
Next, the results have been discussed with the market experts from
different sectors to verify their credibility. Based on this procedure
it was concluded that prices were not changed due to the BTV8
epidemic, except for the export heifer prices. The latter price
increase was for 50% attributed to the decreased supply of export
heifers from BTV8 infected EU member states and for 50%
attributed to an increased worldwide demand for dairy milk and
therefore cattle, so 50% of the price increase was included in the
calculations.
The inputs for the calculation of the possible losses due to a
BT2008-NV epidemic were in most cases the same as assumed for
the BTV-8 epidemic in 2007 [11]. Only the epidemiological inputs
for mortality and morbidity and the number of infected farms
differed. The new BT2008-NV inputs were based on the opinion
of five BT experts: four epidemiologists and one veterinarian
closely involved with the Dutch BTV-8 epidemic and related
research. The experts have attended a discussion meeting and
agreed on the new inputs and assumptions of the model with
regard to the BT2008-NV epidemic. The inputs are given in
Table 1.
The expected number of infected holdings in the baseline
scenario BT2008-NV was assumed to be equal to the number of
non-infected farms in 2007. This assumption is based on the fact
that the farm level seroprevalence was very high at the end of 2007
[11] and assuming that infected animals are not susceptible for the
infection in the next year. Both assumptions indicate that the
number of susceptible animals in 2008 was very low (Table 2). The
mortality and morbidity rates in the northern region during the
BT2008-NV epidemic were assumed to equal the rates in the
central region in 2007. This because the rates in 2007 were higher
in the central region compared to the northern and southern
regions, suggesting that the rates increase with the number of
infected farms and animals in the region. The mortality and
morbidity rates in the central region in 2008 were assumed to be
85% of the rates in the central region in 2007. This reduction is
assumed since the number of new infected farms in that region in
2008 would be lower than in 2007. Finally, the mortality and
morbidity rates in the southern region in 2008 were assumed to be
50% of the rates in the southern region in 2007. This reduction
reflects also the reduction in new infected farms in 2008 compared
to 2007.
Table 1. Input for the cost calculations regarding BTV-8 vaccination strategies.
Input parameters
For all cattle farms sheep farms goats farms
Var. Description Farms dairy veal others dairy herding breeding fattening hobby dairy fattening hobby
nj # farms 22,301 3,174 10,771 30 40 10,432 2,000 51,881 351 45 74,824
dk # doses per animal 2 2 2 1 1 1 1 1 1 1 1
Vet1 Call out charge vet J/visit
1 20.58
hj # hours to vaccinate a farm
1 1 2 1 1 1 1 1 0.5 1 1 0.5
Vet2 Hourly rate vet J/hour
1 116.17
naj # animals to be vaccinated
all animals 113 266 35 245 1,044 88 58 6 612 297 4
only adults 64 0 18 240 448 51 0 4 447 0 3
M Materials costs J/animal 0.02
V Vaccine price J/dosage
1 0.40
R Registration costs J/animal 0.05
1for the calculation of the full costs, i.e. without the EU compensation.
doi:10.1371/journal.pone.0019612.t001
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Different estimates of mortality and morbidity rates for cattle
during the 2007 epidemic exist and therefore two different
epidemiological scenarios were assumed in this study: ES1 and
ES2. The rates for scenario ES1 were based on a longitudinal
study of 585 BTV-8 confirmed-infected cattle farms [4], whereas
the rates in scenario ES2 are based on a longitudinal study of 72
dairy farms [12,13].
Effect of vaccination
The economic benefit of vaccination against BTV-8 is defined
as the reduction of the financial impact due to vaccination caused
by a BTV-8 epidemic from July 2008 to July 2009 compared to
the baseline scenario BT2008-NV. This reduction is due to the
effect of the vaccine on the health state of the vaccinated animals,
with the consequence that less control measures are needed to
control the epidemic. We assumed that animals were vaccinated a
few weeks before being exposed to BTV-8 so that the effect of
vaccination was maximal. Vaccination will reduce the mortality
and morbidity rates to zero because it is assumed that vaccination
will induce full clinical protection [14,15]. So, vaccinated animals
will not get diseased or die as a result of BT infection. As a
consequence, the production losses due to a BTV-8 infection will
be absent and no treatments are needed to help sick animals
recover. We assumed that vaccination does not induce negative
health effects to the animals [7,16]. Long term effects of
vaccination beyond 2008, like i.e. the benefit of elimination and
consequently a potential change of the countries health status,
were behind the scope of this research. It was assumed that, only
costs are made for diagnosis on vaccinated farms if they were
nominated to export production animals as a full protection
needed to be guaranteed.
Cost calculations of the vaccination strategies
The total costs of the defined vaccination strategies (Ci) were
calculated as follows:
Ci~
X
j
nj:dk: Vet1zhj:Vet2znaj MzVzR ðÞ
  
, ð2Þ
where nj represents the number of farms of a specific type j that
should be vaccinated, dk the number of doses that an animal type
k needs, Vet1 the standard call out charge and Vet2 the hourly
rate of an veterinarian. Hence, hj represents the number of hours
needed to vaccinate all animals at farm j, naj the number of
animals to be vaccinated, M the costs for materials needed per
animal, V the costs of one dosage vaccine, and R the costs for
registration of the vaccinated animal.
The European Commission decided in 2008 to provide
financial support to the emergency Bluetongue vaccination
programmes of Member States. The financial contribution
supported vaccination plans at a rate of 100% of the vaccine’s
supply cost and 50% of the costs incurred while carrying out the
vaccination, up to certain ceilings [17]. The costs of the
vaccination strategies adjusted for the EU compensation
(C(EU)i) were calculated as follows:
Ctotal~Ci{C(EU)i ð3Þ
where,
C(EU)i~
X
j
X
k
nk:Vaccj,k ð4Þ
In this equation, Vaccj,k represents the vaccination costs per farm
of type j for animal types k, which were calculated based on the
following ceilings as defined by the EU Commission [17]:
Vacci,cattle~50%:dk: Vet1zhj:Vet2znaj MzR ðÞ
  
,
Vacci,cattlev2:00
Vacci,cattle~2:00A=animal,
Vacci,cattle§2:00
Vacci,sheep=goats~50%:dk: Vet1zhj:Vet2znaj MzR ðÞ
  
,
Vacci,sheep=goatsv0:75
Vacci,sheep=goats~0:75A=animal,
Vacci,sheep=goats§0:75
ð5Þ
The inputs for the calculations are listed in Table 2. The
demographic input on farm numbers and number of animals per
farm originated from the Statistics Netherlands database [18]. The
numbers on the cattle were based on the census conducted in May
2006 and the numbers related to sheep and goats on the census of
November 2004. Based on the census data the number of animals
present at a farm per year was estimated and used for the
calculations. The cattle sector also included the export related
firms, i.e. six export quarantine farms and 34 exporters (of which
some have their own export quarantine farm). The numbers of
sheep and hobby farms included also unregistered holdings, which
Table 2. Input for the calculation of losses of a ‘‘BTV-8 2008 epidemic without vaccination.’’
Cattle Sheep Goats
Description North Middle South North Middle South -
% infected farms 17.30 0.56 2.68 30.39 30.39 30.39
Estimated # Infected farms 1,505 98 188 7,165 9,286 3,114 40
Mortality rate A
1 (#/100 animal months) 0.225 0.196 0.085 1.233 1.048 0.799 0.000
B( #/100 animal months) 0.256 0.218 0.200 1.233 1.048 0.799 0.000
Morbidity rate A (#/100 animal months) 6.480 5.508 3.223 6.484 5.511 3.997 1.300
B( #/100 animal months) 0.808 0.687 0.514 6.484 5.511 3.997 1.300
1Mortality rates A and B are based on different estimates for the epidemic in 2007 (see Velthuis, et.al., 2010).
doi:10.1371/journal.pone.0019612.t002
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75% of the goat holdings were not registered [19]. All other inputs
were based on expert opinions of either the vaccine producer or
veterinarians.
Economic criteria to rank the vaccination strategies
The different vaccination strategies are ranked bythe benefit-
cost ratios or the total net returns. The benefit-cost ratio equals the
total benefits divided by the total cost and shows how much
benefits are generated at costs of one Euro. When it exceeds one,
the strategy is economically efficient and the higher the ratio the
better the efficiency. The net returns equal the total benefits minus
the total costs. It shows how high the extra benefits are in relation
to the total costs.
Sensitivity analysis
A sensitivity analysis was performed to assess and identify the
inputs that most influence the net benefits. Each individual
input was changed with +10% and 210% and the total net
benefit was calculated. This analysis was carried out using the
add-in software TopRank 5.5 for Excel of Palisade Decision
Tools [20].
Results
Financial impact of BT2008-NV epidemic
The financial impact of the BT2008-NV epidemic was
estimated to be J40.9 and J41.3 mln for the epidemiological
scenarios ES1 and ES2, respectively (Table 3). Most losses would
be for the sheep breeding farms, the dairy export firms and the
dairy farms being J12.6, J12.6 and J11.3 mln, respectively,
whereas smallest losses could be expected for the goat farms, veal
calf farms and sheep export firms. Looking at the different cost
categories, it can be observed that the production losses resulted in
the highest impact, 52,8% and 55,2% of the total net costs,
respectively, followed by the financial impact of the expected
control measures, i.e. 33.2% and 32.8%, respectively.
Benefits of vaccination strategies
Most benefits (i.e. reduction in losses compared to the BT2008-
NV epidemic) are gained with strategies A, B and C, which are
about J33.9, J32.0 and J31.3 mln, respectively (Figure 1).
Whereas, strategy G brings the least benefits (J10.8 mln) followed
by strategy F (J13.1 mln). The difference between the two
epidemiological scenarios ES1 and ES2 is relatively small, i.e. this
Table 3. Financial impact (* J1000) of the BT2008-NV epidemic according to farm type, sector and overall.
Production losses Diagnosis Treatment Control Total
Farm type/sector ES1 ES2 - ES1 ES2 ES1 ES2
Cattle
Dairy 9,861.9 10,212.7 0.0 867.7 110.5 949.9 11,679.5 11,273.1
Veal calf 19.1 19.1 - - - 0.0 19.1 19.1
Other cattle 465.4 522.3 0.0 50.4 6.7 0.0 515.8 529.1
Susp test neg
1 - - 154.2 - - - 154.2 154.2
Screening - - 182.4 - - - 182.4 182.4
Export - - - - - 12,576.0 12,576.0 12,576.0
Cattle subtotal 10,346.3 10,686.0 336.6 918.1 117.3 13,525.9 25,126.9 24,665.8
Sheep
Dairy 11.1 11.1 0.0 4.4 4.4 0.0 15.6 15.6
Herding 138.5 138.5 0.2 198.2 198.2 0.0 337.0 337.0
Breeding 9,590.3 9,590.3 61.3 2,959.3 2,959.3 1.3 12,612.2 12,612.2
Fattening 1,000.0 1,000.0 11.8 871.0 871.0 0.5 1,883.3 1,883.3
Hobby 488.7 488.7 64.1 157.4 157.4 0.0 710.3 710.3
Susp test neg - - 91.7 - - - 91.7 91.7
Screening - - 26.1 - - - 26.1 26.1
Export - - - - - 1.8 1.8 1.8
Sheep subtotal 11,228.7 11,228.7 255.3 4,190.3 4,190.3 3.6 15,677.9 15,677.9
Goats
Dairy 0.4 0.4 0.6 0.6 0.6 - 1.6 1.6
Fattening 0.0 0.0 0.0 0.0 0.0 - 0.0 0.0
Hobby 0.0 0.0 0.8 0.2 0.2 - 1.0 1.0
Susp test neg - - 3.3 - - - 3.3 3.3
Screening - - 26.1 - - - 26.1 26.1
Export - - - - - 18.2 18.2 18.2
Goat sector subtotal 0.4 0.4 30.8 0.8 0.8 18.2 50.2 50.2
Total 21,575.5 22,811.6 622.6 5,109.3 4,308.4 13,547.7 40,855.1 41,290.3
1Suspected farm but tested negative.
doi:10.1371/journal.pone.0019612.t003
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only the results based on ES1 in the remainder of this paper.
Vaccination costs
The costs of the vaccination strategies varied widely. Strategy G
costs only J2.8 mln or J1.2 mln, with or without EU
compensations respectively, whereas strategy A costs almost 10
times more, i.e. J26.6 mln or J11.3 mln (Figure 1). Vaccination
costs differed among farm types (Table 4). To vaccinate an average
dairy farm the costs sum up to J383 per farm if all animals should
be vaccinated or J333 if only adults should be vaccinated,
whereas vaccination of a dairy sheep farm costs J250 to J252 and
of a dairy goat farm J347 to J425.
The vaccination costs are almost twice as high for the cattle
sector as for the sheep and goat sectors (Table 4). This is mainly
because cattle must be vaccinated twice and sheep and goats only
once. If only adults are vaccinated, it saves J3.3 mln vaccination
costs in the cattle sector and J1.0 mln in the sheep sector, whereas
only J0.1 mln in the goat sector. The vaccination costs at farm
level vary widely due to economies of scales where the costs per
animal are lower for larger farms than for smaller farms, although
larger farms have higher total cost. Compare for example, the cost
per farm or animal for the sheep breeding farms (J206 per farm
and J1.40 per animal) with the sheep hobby farms (J82 per farm
and J10.50 per animal). The relative size of the EU compensation
for the vaccination programmes varies much between farm types,
i.e. between 3% and 85% per farm type. This variation is caused
by the difference in farm size, but also by the ceilings per animal
that are configured by the Commission. The labour costs for the
veterinarian are relatively high (varying between 21% and 98%).
This is because only a veterinarian is allowed to vaccinate the
animals in the Netherlands and labour costs in general are high
compared to other cost components.
Costs compared to the benefits
In Figure 2, the benefits of the vaccination strategies are plotted
against the corresponding vaccination costs. The dashed lines
represents the least cost - highest benefit frontiers for the ES1
scenario, with and without EU compensation respectively. The
points located on the frontier are considered as the most efficient
set of strategies, whereas the points below the frontier as
inefficient. For each strategy below the frontier, there is at least
one strategy on the frontier that has either lower costs and/or
more benefits or both. The least-cost frontier is excluding
strategies G, E and H, indicating that these are less efficient than
others.
The overall benefit-cost ratios (for the three sectors together) are
for all vaccination strategies efficient, i.e. higher than one (Table 5).
The highest benefit-cost ratio is expected for scenario F (7.68),
followed by strategy D (5.28). Strategy G has the third best benefit-
cost ratio (3.83), but is less efficient than F and D according to the
least cost – highest benefit frontier. The benefit-cost ratios for the
goat sector are low and are, therefore, not efficient suggesting that
vaccinating goats next to sheep or cattle is from an economic point
Figure 1. Benefits, costs and cost-benefit ratios of the eight vaccination strategies for the two epidemiological scenarios 1 and 2
(Sc1 and Sc2) where the strategies are ranked descending according to the net benefits of scenario 2.
doi:10.1371/journal.pone.0019612.g001
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Vaccination costs (J) % of the Vaccination costs
Per (sub) sector Per farm Per animal
1 Financed by EU Veterinary labour
Farm type All Only All Only All Only All Only All Only
Animals
2 Adults
3 animals adults animals adults animals adults animals adults
Cattle
Dairy 8,540.2 7,433.8 383 333 3.29 5.24 61% 38% 36% 41%
Veal calf 2,002.2 0.0 631 0 4.74 - 42% - 40% -
Other cattle 2,995.5 2,801.9 308 288 8.39 18.56 24% 11% 44% 47%
Sector total 13,537.8 10,235.7
Sheep
Dairy 7.6 7.5 252 250 1.03 1.04 70% 70% 54% 55%
Herding 48.0 18.5 1,200 463 0.60 1.03 85% 70% 21% 55%
Breeding 2,149.4 1,674.7 206 161 1.40 3.17 54% 24% 66% 85%
Fattening 420.9 0.0 210 0 1.34 - 56% - 65% -
Hobby 4,272.1 4,183.8 82 81 10.50 19.12 7% 4% 96% 98%
Sector total 6,898.0 5,884.5
Goats
Dairy 149.0 121.7 425 347 0.69 0.78 80% 77% 32% 39%
Fattening 12.4 0.0 276 0 0.93 - 73% - 49% -
Hobby 6,014.5 5,985.6 80 80 21.93 28.12 3% 3% 98% 98%
Sector total 6,175.9 6,107.4
1Per vaccinated animal.
2These number equal vaccination strategy A.
3These numbers equal vaccination strategy B.
doi:10.1371/journal.pone.0019612.t004
Figure 2. Least cost - highest benefit frontier for the eight vaccination strategies.
doi:10.1371/journal.pone.0019612.g002
Financial Evaluation of Bluetongue Vaccination
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19612of view not sensible. The benefit-cost ratios of the sheep and cattle
sectors exceed one for all strategies, where the ratios of the sheep
sector are for all vaccination strategies higher than the cattle sector
ratios.
Not all farm types have efficient ratios (Table 5). The ‘other
cattle farms’, the ‘sheep hobby farms’ and all goat farms have
benefit-cost ratios lower than one, suggesting that it might be
better to exclude them from a vaccination strategy from an
economic point of view. Moreover, some farms/holdings have
infinitive benefit-cost ratios. These are the veal calf farms and the
export related cattle farms for the strategies where they do not
have to vaccinate (no vaccination costs) but where they have
economic benefits: some for the veal calf farms and extensive farms
benefits for the export related cattle firms.
The net returns (for the three sectors together) have a positive
value for all vaccination strategies indicating that applying a
vaccination strategy is better than doing nothing (Table 6). The
highest net returns are expected for strategies C and D (i.e. about
J19 mln) followed by strategy H (i.e. around J14 mln), although
strategy H is less efficient than others according to the least-cost
frontier.
When only adult cattle are vaccinated, the net returns increases
by at least J2.5 mln (e.g. comparing strategy A with B). This
indicates that it is not cost efficient to vaccinate young stock. This is
because the vaccination costs increases by J4.4 mln if young
animals in the cattle, sheep and goat sectors would also be
vaccinated, whereas the reduction in losses is only 1.8 mln Euros
(comparing strategy A with B). The limited reduction in losses is due
to the fact that most production losses are related to adult animals
and moreover most diseased animals were adults [11]. Excluding
hobby farms (and the category ‘‘other cattle’’ farms) from a
vaccination strategy would increase the net returns of the sectors
with about J2.3 million for cattle and J3.5 million for sheep.
Summarizing, strategy D (vaccination of all adult sheep at
professional farms of the Netherlands and all adult cattle in the
four Northern provinces) is the best strategy to apply based on
economic criteria. Strategies C (vaccination of all adult sheep and
cattle at professional farms in the Netherlands) and F (vaccination
of all adult sheep at professional farms in the Netherlands) are the
second and third best strategies. The strategies E (vaccination of all
adult cattle at professional farms in the Netherlands), G
(vaccination of all adult cattle at professional farms in the four
Northern provinces) and H (vaccination of 80% of the adult sheep
and cattle in the Netherlands) have more efficient alternatives and
should therefore not be considered. Whereas the strategies A
(vaccination of all sheep, cattle and goats of the Netherlands) and
(to a less extend) B (vaccination of all adult sheep, cattle and goats
of the Netherlands) are ranked last.
Sensitivity analysis
The effect of individual inputs on the total net returns for the
different vaccination strategies is limited (Figure 3). The number of
animals per farm and the number of farms in the Netherlands
were most influential. The time needed to vaccinate a farm is one
of the most influential inputs, although it affects the net returns
little.
Discussion
The objective of this study was to rank eight vaccination
strategies based on efficiency (i.e. net cost in relation to prevented
losses or benefits) for controlling the BTV-8 epidemic in 2008 in
the dairy, sheep and goat sectors. This was done using an
economic model that includes the Dutch professional cattle, sheep
and goat sectors together with the hobby farms. All financial costs
and benefits (that can be linked to the BTV-8 epidemic and/or the
Table 5. Estimated benefit-cost ratios of the eight defined BTV-8 vaccination strategies for different farm types, for the three
sectors and for all sectors overall.
Benefi- cost ratios of the different vaccination strategy (A–H)
Farm type/sector A B C D (E)
a F (G) (H)
Dairy 1.17 1.35 1.35 1.35 1.35 - 1.35 1.35
Veal calf 0.01 ‘‘‘‘ - ‘‘
Other cattle 0.17 0.18 0.18 0.18 0.18 - 0.18 0.18
Export related 0.00 ‘‘‘‘ - ‘‘
Cattle sector 1.35 1.79 1.79 3.83 1.79 - 3.83 1.97
Dairy sheep 2.06 2.08 2.08 2.08 - 2.08 - 2.08
Traditional herding 7.02 18.18 18.18 18.18 - 18.18 - 18.18
Breeding 5.87 7.53 7.53 7.53 - 7.53 - 7.53
Fattening 4.47 - - - - - - -
Hobby 0.17 0.17 - - - - - 0.17
Sheep sector 2.27 2.34 7.68 7.68 - 7.68 - 2.34
Dairy goat 0.01 0.01 - - - - - -
Fattening 0.00 - - - - - - -
Hobby 0.00 - - - - - - -
Goat sector 0.00 0.00 - - - - - -
All sectors 1.27 1.44 2.62 5.28 1.79 7.68 3.83 2.10
Ranking 8 7 4 2 (6) 1 (3) (5)
aThe strategies between parentheses are less efficient than others: see least cost frontier of Figure 2.
doi:10.1371/journal.pone.0019612.t005
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affected farm sector (related to the vaccination strategies in the
cattle, sheep and goats), the affected related industry and the
controlling authorities were included, regardless of who is paying.
It can be concluded that strategies F (where all adult sheep at
professional farms are vaccinated) and C (where all adult sheep
and cattle at professional farms are vaccinated) are the best
strategies based on the benefit-cost ratio and that C and D (where
all adult sheep at professional farms and all adult cattle in the four
Northern provinces are vaccinated) are best based on the net
return.
Hence the decision of the vaccination strategies depends on the
economic criteria used, but the top three efficient strategies include
the same strategies, namely C, D and F. Which criteria is best is
subject to the preference of the decision maker. The cost-benefit
ratio where costs are divided by the benefits is a good indicator for
Table 6. Net returns of the eight defined BTV-8 vaccination strategies for different farm types, for the three sectors and for all
sectors together.
Net returns (* J1,000) of the different vaccination strategy (A–H)
Farm type/sector A B C D (E)
a F (G) (H)
Dairy 1,477 2,583 2,583 795 2,583 0 795 2,067
Veal calf 21,983 19 19 6 19 0 6 15
Other cattle 22,480 22,286 22,286 2432 22,286 0 2432 21,829
Export related 7,567 7,567 7,567 7,567 7,567 0 7,567 7,567
Cattle sector 4,735 8,037 8,037 7,983 8,037 0 7,983 7,943
Dairy sheep 8 8 8 8 0 8 0 6
Traditional herding 289 318 318 318 0 318 0 255
Breeding 10,462 10,936 10,936 10,936 0 10,936 0 8,749
Fattening 1,462 0 0 0 0 0 0 0
Hobby 23,562 23,473 0 0 0 0 0 22,779
Sheep sector 8,750 7,881 11,354 11,354 0 11,354 0 6,305
Dairy goat 2147 21 2 0 00000 0
Fattening 21 2 0 00000 0
Hobby 26,014 25,986 0 0 0 0 0 0
Goat sector 26,170 26,106 0 0 0 0 0 0
All sectors 7,315 9,812 19,391 19,337 8,037 11,354 7,983 14,248
Ranking 8 5 1 2 (6) 4 (7) (3)
aThe strategies between parentheses are less efficient than others: see least cost frontier of Figure 2.
doi:10.1371/journal.pone.0019612.t006
Figure 3. The maximal difference in net return caused by the most influential input when changing it with 10%.
doi:10.1371/journal.pone.0019612.g003
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be most efficient if the benefits are relatively high compared to the
costs. The net return where the difference between the costs and
benefits are calculated indicates how high the returns are [21].
Both indicators are used in decision making and which one to
prefer is mostly based on the preference of the decision maker.
Epidemiological assumptions had to be made as at the time of
this study not all epidemiological knowledge was available. One of
the assumptions was that all farms that were not infected in 2007
would be infected in the 2008 epidemic if no vaccination strategy
would be applied. As we now know that BT virus dynamics are
predominantly driven by environmental conditions (e.g. temper-
ature, and vector habitats) [9] but might also be driven by housing
systems or other factors this is a questionable assumption. So the
losses prevented in all vaccination scenarios could be overestimat-
ed. However, the ranking of the strategies would stay the same in
case of a reduced infection rate. Also, new mortality rates have
been reported for the Netherlands suggesting that the mortality in
scenario B was underestimated [22], suggesting that our estimation
of the prevented losses was underestimated. Again, we think that
the ranking would not be affected, as the underestimations applies
to all vaccination scenarios. Another assumption made is that the
presence of vaccinated animals in an area will not result in a
benefit for other non-vaccinated animals, due to a reduced
transmission rate. This assumption was made as a lot knowledge
about BTV8 transmission was unknown at the time of this study.
This assumption might lead to an underestimation of the losses
prevented for scenarios where some animal groups were excluded.
The efficiency of vaccination strategy D might therefore be
underestimated compared to strategy C.
We assumed that animals were vaccinated a few weeks before
being exposed to BTV-8 so that the effect of vaccination was
maximal. At the time of this study it was a hard assumption, as the
vaccine was available at the start of June 2008 and the first
outbreaks in previous 2006 and 2007 were observed at the start of
August and at the end of July: leaving 8 weeks to vaccinate the
population. However, the logistic plan behind the vaccination
campaign was ready at the time of this study and showed that most
animals could be vaccinated within a short time frame.
This study included a time horizon of only one year and
excluded therefore the longer term benefits of eradicating BTV-8
from the Netherlands and the EU. Including a longer time horizon
would include other effects like eradication and reestablishment of
the export markets, but epidemiological knowledge regarding the
developments in the future was at that time missing. For example,
are naturally infected animals and vaccinated animals protected
against BTV-8 for the rest of their lives or only for a shorter
period? How long would maternally gained immunity proceed?
How long will it take before eradication is achieved in the
Netherlands, the neighbouring countries (Belgium and Germany)
and the whole of the EU?
This study included all affected sectors: cattle, sheep and goats.
Not only the primary producers were considered, but also other
chain partners, like slaughterhouses or dairy firms. However, after
the first round of discussions with sector experts, no negative or
positive effects of the BTV-8 epidemic of these firms were
indicated, which was confirmed by the statistical analysis of
product prices. The effect of vaccination on the consumption of
animal products was also expected to be zero. Note that the
analysis of the price changes was based on the monthly average
national prices of the different animals and animal products. To
check for missed price changes and/or changes that were caused
by other factors market experts were asked to give their expert
opinion. This analysis provided us an idea whether prices change
at National level but not for the farms within a restriction zone
compared to outside a restriction zone. As the analysis is focuses
on sectors the latter is less important. The economic benefits of the
veterinarians due the BTV-8 epidemic were not quantified
explicitly. But the benefits can be high when looking to the
veterinary labour costs relatively to the total vaccination costs.
The results show that it is not cost efficient to vaccinate goats.
Not a lot of severe clinical symptoms [23] and consequently
negative production effects were observed in the goat populations
during the BTV-8 epidemic. Furthermore, there is no economic
important export market for the goat sector that should be
maintained. Therefore, almost no benefits are expected for this
sector if vaccination would be applied here, resulting in an benefit-
cost ratio lower than one and a negative net return.
Vaccinating hobby farms is not cost efficient in a time horizon
of a year. This is mainly because the vaccination costs are
relatively high (per farm or animal) due to the high costs for the
veterinarian. Based on economic reasoning, excluding the hobby
farms for a vaccination strategy is for this reason sensible.
However, note that the importance of economic criteria for hobby
farmers is less than for commercial farms so giving them the
possibility to vaccinate for animal welfare reasons would be fair.
Epilogue
Shortly after finishing this study the Dutch Government had to
decide on the strategy to implement. They decided to apply a
voluntary vaccination program aiming a vaccination coverage of
80% in order to get the financial support from the EU. The 80%
coverage rule of the EU was based on the assumption that 80%
coverage would be needed to prevent between-herd transmission
and that eradication might become feasible. The UK (England
and Wales) also applied a voluntary program, whereas other
countries applied mandatory vaccination programs (Belgium,
Germany, Luxembourg and the Czech Republic).
The estimated vaccination coverage varied from one country to
the other. In the Netherlands the estimated vaccination coverage
was: 73% in sheep, 71% in dairy farms, 43% in goat farms and
67% in hobby holdings [24]. In the UK a coverage of .80% was
achieved within areas where BTV transmission has been
confirmed in 2007, but it was about 40% in areas where no
BTV had been reported before. In Germany, approximately 70%
of cattle and 90% of sheep in the infected areas were vaccinated
[25].
Again a voluntary vaccination program was implemented in the
Netherlands in 2009, although now no financial support by the
EU was available. The willingness of Dutch farmers to vaccinate
was significantly lower that year, namely an estimated 42% in
sheep farms, 58% in dairy farms, 19% in goat farms and 49% in
hobby farms [24]. No new BTV-8 infections were reported in that
year [26].
A voluntary program as implemented in the Netherlands in
2008 might be less efficient as other compulsory strategies.
However, other than economic criteria are used in making the
decision on a vaccination strategy. Mandatory strategies must first
be approved by the EU and may carry additional administrative
requirements. This, in combination with delay that may result
from mandatory vaccination strategies is the main reason why not
every country choices for a mandatory strategy. Furthermore, the
Dutch government imposes increasingly the responsibility for
disease outbreaks back to the industry. And, additionally the
negative attitude of farmers against compulsory vaccination is
partly caused by the negative experience they had with a BVDV-
contaminated BHV type 2 vaccine used in an earlier compulsory
vaccination campaign [24,27]. This contaminated vaccine caused
Financial Evaluation of Bluetongue Vaccination
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still triggers some distrust with respect to vaccination campaigns in
Dutch cattle farmers [24].
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